Top Markets
Coin of the day
Immune Therapeutics, Inc. Immune Therapeutics, Inc.

Immune Therapeutics, Inc.

IMUN
Rank in Stocks #41151
Immune Therapeutics, Inc. currently conducts no significant business... Immune Therapeutics, Inc. currently conducts no significant business operations. Formerly known as TNI BioTech, Inc., the company adopted its present name in October 2014. Its corporate headquarters are situated in Orlando, Florida.
Share Price
$0.08
Last synced: 2023-11-13
Market Cap
$38.70K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Immune Therapeutics, Inc. (IMUN)

Category

P/E ratio for Immune Therapeutics, Inc. (IMUN)
P/E ratio as of 2026 TTM: 0
According to Immune Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Immune Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.05 -
US
31.14 -
NL
- -
CH
- -
KR
19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.